In a prospective phase II trial, 6 patients with well‐differentiated (WD) pancreatic NET and 6 with poorly‐differentiated (PD) NEC (but with Ki‐67 values between 20% and 50%) received sunitinib following disease progression.70 The gene discussed is MKI67; the disease is neuroendocrine carcinoma.